Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) EVP Simrat Randhawa sold 23,124 shares of Dianthus Therapeutics stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $106.41, for a total value of $2,460,624.84. Following the transaction, the executive vice president owned 4,000 shares in the company, valued at approximately $425,640. This represents a 85.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Dianthus Therapeutics Price Performance
Shares of Dianthus Therapeutics stock traded up $1.61 during trading hours on Thursday, hitting $107.85. The company’s stock had a trading volume of 355,690 shares, compared to its average volume of 931,557. Dianthus Therapeutics, Inc. has a 12 month low of $23.70 and a 12 month high of $117.88. The stock has a 50 day moving average of $104.65 and a 200 day moving average of $88.52. The company has a market capitalization of $5.90 billion, a PE ratio of -25.99 and a beta of 1.24.
Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. The business had revenue of $0.76 million for the quarter, compared to the consensus estimate of $0.30 million. Equities analysts expect that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current year.
Wall Street Analyst Weigh In
Check Out Our Latest Analysis on DNTH
Hedge Funds Weigh In On Dianthus Therapeutics
Several hedge funds have recently modified their holdings of DNTH. BlackRock Inc. acquired a new stake in shares of Dianthus Therapeutics in the second quarter valued at about $401,990,000. California State Teachers Retirement System boosted its position in Dianthus Therapeutics by 10,003.2% during the second quarter. California State Teachers Retirement System now owns 4,100,301 shares of the company’s stock valued at $399,697,000 after purchasing an additional 4,059,717 shares during the last quarter. Wellington Management Group LLP grew its stake in Dianthus Therapeutics by 3,366.9% in the third quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock valued at $101,431,000 after purchasing an additional 2,503,311 shares in the last quarter. Vestal Point Capital LP grew its stake in Dianthus Therapeutics by 88.2% in the second quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock valued at $59,616,000 after purchasing an additional 1,499,931 shares in the last quarter. Finally, State Street Corp increased its position in shares of Dianthus Therapeutics by 124.7% during the 4th quarter. State Street Corp now owns 1,507,619 shares of the company’s stock worth $62,129,000 after purchasing an additional 836,571 shares during the last quarter. Institutional investors own 47.53% of the company’s stock.
About Dianthus Therapeutics
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.
Read More
- Five stocks we like better than Dianthus Therapeutics
- The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
- NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
- Dropping the Dough: Yum! Brands Strategically Trims the Fat
- These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
